Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ernexa Therapeutics Inc.NTN · Entity 8278 | 10% owner | June 03, 2020 | June 04, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ernexa Therapeutics Inc.
Report date June 03, 2020 · Filed June 04, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 276,100 |
Reported balance
After 2020-06-03 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-06-03 · Sale · Disposed 21,932 · Balance 276,100 F1: The reporting person is no longer a 10% Owner after the sale of the 21,932 shares reported on the transaction date. This filing also constitutes a Form 4 "exit filing" for the reporting person as the reporting person is no longer subject to Section 16 under the Securities Exchange Act of 1934, as amended, as of the date of this filing. F2: The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from not less than $1.00 to not more than $1.12. The reporting person undertakes to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the ranges set forth in the footnotes to this Form 4 that report a range of prices. F3: Shares held of record by Matador Capital Partners, L.P. The reporting person is the managing member of BFK Investments LLC, which is the general partner of Matador Capital Partners, L.P. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 12,346 |
Reported balance
Holding disclosure · report date 2020-06-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 12,346 |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is no longer a 10% Owner after the sale of the 21,932 shares reported on the transaction date. This filing also constitutes a Form 4 "exit filing" for the reporting person as the reporting person is no longer subject to Section 16 under the Securities Exchange Act of 1934, as amended, as of the date of this filing.
F2: The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from not less than $1.00 to not more than $1.12. The reporting person undertakes to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the ranges set forth in the footnotes to this Form 4 that report a range of prices.
F3: Shares held of record by Matador Capital Partners, L.P. The reporting person is the managing member of BFK Investments LLC, which is the general partner of Matador Capital Partners, L.P. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2020 Filed Jun 4, 2020 17:50 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | SaleCommon Stock | 21,932 | $1.10 | $24,059.40 |
DisclosureSEC source: 0001493152-20-010545 · ownership.xml · nonDerivative · entry 1 Berg Jeffrey Alan · CIK 0001443481 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 276,100 F1 · shares: The reporting person is no longer a 10% Owner after the sale of the 21,932 shares reported on the transaction date. This filing also constitutes a Form 4 "exit filing" for the reporting person as the reporting person is no longer subject to Section 16 under the Securities Exchange Act of 1934, as amended, as of the date of this filing. F2 · price: The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from not less than $1.00 to not more than $1.12. The reporting person undertakes to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the ranges set forth in the footnotes to this Form 4 that report a range of prices. F3 · ownership.nature: Shares held of record by Matador Capital Partners, L.P. The reporting person is the managing member of BFK Investments LLC, which is the general partner of Matador Capital Partners, L.P. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 02, 2020 Filed Jun 3, 2020 16:01 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | SaleCommon Stock | 30,730 | $0.99 | $30,422.70 |
DisclosureSEC source: 0001493152-20-010447 · ownership.xml · nonDerivative · entry 2 Berg Jeffrey Alan · CIK 0001443481 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 297,440 F3 · price: The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from not less than $0.95 to not more than $1.05. The reporting person undertakes to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the ranges set forth in the footnotes to this Form 4 that report a range of prices. F2 · ownership.nature: Shares held of record by Matador Capital Partners, L.P. The reporting person is the managing member of BFK Investments LLC, which is the general partner of Matador Capital Partners, L.P. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 16:01 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | SaleCommon Stock | 30,000 | $1.06 | $31,770.00 |
DisclosureSEC source: 0001493152-20-010447 · ownership.xml · nonDerivative · entry 1 Berg Jeffrey Alan · CIK 0001443481 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 328,170 F1 · price: The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from not less than $1.02 to not more than $1.08. The reporting person undertakes to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the ranges set forth in the footnotes to this Form 4 that report a range of prices. F2 · ownership.nature: Shares held of record by Matador Capital Partners, L.P. The reporting person is the managing member of BFK Investments LLC, which is the general partner of Matador Capital Partners, L.P. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 13:32 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | SaleCommon Stock | 25,000 | $1.06 | $26,450.00 |
DisclosureSEC source: 0001493152-20-010219 · ownership.xml · nonDerivative · entry 2 Berg Jeffrey Alan · CIK 0001443481 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 358,170 F3 · price: The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from not less than $1.05 to not more than $1.12. The reporting person undertakes to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the ranges set forth in the footnotes to this Form 4 that report a range of prices. F2 · ownership.nature: Shares held of record by Matador Capital Partners, L.P. The reporting person is the managing member of BFK Investments LLC, which is the general partner of Matador Capital Partners, L.P. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 13:32 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | SaleCommon Stock | 12,338 | $1.08 | $13,349.72 |
DisclosureSEC source: 0001493152-20-010219 · ownership.xml · nonDerivative · entry 1 Berg Jeffrey Alan · CIK 0001443481 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 383,170 F1 · price: The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from not less than $1.05 to not more than $1.17. The reporting person undertakes to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the ranges set forth in the footnotes to this Form 4 that report a range of prices. F2 · ownership.nature: Shares held of record by Matador Capital Partners, L.P. The reporting person is the managing member of BFK Investments LLC, which is the general partner of Matador Capital Partners, L.P. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 27, 2020 Filed May 29, 2020 10:11 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | SaleCommon Stock | 5,000 | $1.11 | $5,540.00 |
DisclosureSEC source: 0001493152-20-010087 · ownership.xml · nonDerivative · entry 2 Berg Jeffrey Alan · CIK 0001443481 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 395,508 F3 · price: The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from not less than $1.08 to not more than $1.13. The reporting person undertakes to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the ranges set forth in the footnotes to this Form 4 that report a range of prices. F2 · ownership.nature: Shares held of record by Matador Capital Partners, L.P. The reporting person is the managing member of BFK Investments LLC, which is the general partner of Matador Capital Partners, L.P. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 26, 2020 Filed May 29, 2020 10:11 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | SaleCommon Stock | 20,000 | $1.09 | $21,780.00 |
DisclosureSEC source: 0001493152-20-010087 · ownership.xml · nonDerivative · entry 1 Berg Jeffrey Alan · CIK 0001443481 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 400,508 F1 · price: The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from not less than $1.07 to not more than $1.16. The reporting person undertakes to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the ranges set forth in the footnotes to this Form 4 that report a range of prices. F2 · ownership.nature: Shares held of record by Matador Capital Partners, L.P. The reporting person is the managing member of BFK Investments LLC, which is the general partner of Matador Capital Partners, L.P. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 21:30 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | SaleCommon Stock | 200 | $2.45 | $490.00 |
DisclosureSEC source: 0001493152-19-019726 · ownership.xml · nonDerivative · entry 2 Berg Jeffrey Alan · CIK 0001443481 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 421,100 F2 · ownership.nature: Shares held of record by Matador Capital Partners, L.P. The reporting person is the managing member of BFK Investments LLC, which is the general partner of Matador Capital Partners, L.P. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 20, 2019 Filed Dec 26, 2019 21:30 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | SaleCommon Stock | 1,700 | $2.72 | $4,624.00 |
DisclosureSEC source: 0001493152-19-019726 · ownership.xml · nonDerivative · entry 1 Berg Jeffrey Alan · CIK 0001443481 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 421,300 F1 · price: The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from not less than $2.57 to not more than $2.87. The reporting person undertakes to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the ranges set forth in the footnotes to this Form 4 that report a range of prices. F2 · ownership.nature: Shares held of record by Matador Capital Partners, L.P. The reporting person is the managing member of BFK Investments LLC, which is the general partner of Matador Capital Partners, L.P. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 29, 2017 Filed Oct 3, 2017 20:15 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | GrantCommon Stock | 919 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-17-011198 · form4.xml · nonDerivative · entry 1 Berg Jeffrey Alan · CIK 0001443481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,346 F1 · shares: This restricted stock grant was issued to the reporting person under the NTN Buzztime, Inc. Amended 2010 Performance Incentive Plan and pursuant to the NTN Buzztime, Inc. Non-Employee Director Compensation Policy in lieu of a portion of the annual retainer earned by the reporting person in his capacity as a non-employee director of the issuer with respect to the quarter ended September 30, 2017. This restricted stock grant was fully-vested on the date of grant. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 22:02 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | GrantCommon Stock | 827 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-17-007505 · form4.xml · nonDerivative · entry 1 Berg Jeffrey Alan · CIK 0001443481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,427 F1 · shares: This restricted stock grant was issued to the reporting person under the NTN Buzztime, Inc. Amended 2010 Performance Incentive Plan and pursuant to the NTN Buzztime, Inc. Non-Employee Director Compensation Policy in lieu of a portion of the annual retainer earned by the reporting person in his capacity as a non-employee director of the issuer. This restricted stock grant was fully-vested on the date of grant. Read SEC document |
| November 16, 2016 Filed Nov 17, 2016 01:29 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | PurchaseCommon Stock | 500 | $7.25 | $3,625.00 |
DisclosureSEC source: 0001493152-16-015198 · form4.xml · nonDerivative · entry 7 Berg Jeffrey Alan · CIK 0001443481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 423,000 F1 · ownership.nature: These securities are owned by Matador Capital Partners, L.P. The reporting person is the managing member of BFK Investments LLC, which is the general partner of Matador Capital Partners, L.P. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 16, 2016 Filed Nov 17, 2016 01:29 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | PurchaseCommon Stock | 500 | $7.28 | $3,640.00 |
DisclosureSEC source: 0001493152-16-015198 · form4.xml · nonDerivative · entry 6 Berg Jeffrey Alan · CIK 0001443481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 422,500 F1 · ownership.nature: These securities are owned by Matador Capital Partners, L.P. The reporting person is the managing member of BFK Investments LLC, which is the general partner of Matador Capital Partners, L.P. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 16, 2016 Filed Nov 17, 2016 01:29 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | PurchaseCommon Stock | 720 | $7.26 | $5,227.20 |
DisclosureSEC source: 0001493152-16-015198 · form4.xml · nonDerivative · entry 5 Berg Jeffrey Alan · CIK 0001443481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 422,000 F1 · ownership.nature: These securities are owned by Matador Capital Partners, L.P. The reporting person is the managing member of BFK Investments LLC, which is the general partner of Matador Capital Partners, L.P. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 16, 2016 Filed Nov 17, 2016 01:29 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | PurchaseCommon Stock | 1,000 | $7.23 | $7,230.00 |
DisclosureSEC source: 0001493152-16-015198 · form4.xml · nonDerivative · entry 4 Berg Jeffrey Alan · CIK 0001443481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 421,280 F1 · ownership.nature: These securities are owned by Matador Capital Partners, L.P. The reporting person is the managing member of BFK Investments LLC, which is the general partner of Matador Capital Partners, L.P. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 16, 2016 Filed Nov 17, 2016 01:29 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | PurchaseCommon Stock | 1,200 | $7.21 | $8,652.00 |
DisclosureSEC source: 0001493152-16-015198 · form4.xml · nonDerivative · entry 3 Berg Jeffrey Alan · CIK 0001443481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 420,080 F1 · ownership.nature: These securities are owned by Matador Capital Partners, L.P. The reporting person is the managing member of BFK Investments LLC, which is the general partner of Matador Capital Partners, L.P. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 01:29 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | PurchaseCommon Stock | 500 | $7.33 | $3,665.00 |
DisclosureSEC source: 0001493152-16-015198 · form4.xml · nonDerivative · entry 2 Berg Jeffrey Alan · CIK 0001443481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 419,080 F1 · ownership.nature: These securities are owned by Matador Capital Partners, L.P. The reporting person is the managing member of BFK Investments LLC, which is the general partner of Matador Capital Partners, L.P. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 14, 2016 Filed Nov 17, 2016 01:29 UTC | Ernexa Therapeutics Inc. NTN · Entity 8278 | PurchaseCommon Stock | 1,200 | $7.20 | $8,640.00 |
DisclosureSEC source: 0001493152-16-015198 · form4.xml · nonDerivative · entry 1 Berg Jeffrey Alan · CIK 0001443481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 418,580 F1 · ownership.nature: These securities are owned by Matador Capital Partners, L.P. The reporting person is the managing member of BFK Investments LLC, which is the general partner of Matador Capital Partners, L.P. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.